Show simple item record

Criterios de uso de inhibidores de SGLT2

dc.contributor.authorCaja Costarricense de Seguro Social, Comité Central de Farmacoterapia
dc.date.accessioned2024-05-23T16:49:22Z
dc.date.available2024-05-23T16:49:22Z
dc.date.issued2024-03-11
dc.identifier.otherGM-CCF-1454-2024
dc.identifier.urihttp://hdl.handle.net/20.500.11764/4464
dc.descriptionNOTAes_ES
dc.description.abstractUso de inhibidores de SGLT2es_ES
dc.description.sponsorshipCCSSes_ES
dc.language.isoeses_ES
dc.publisherCCSSes_ES
dc.subjectINHIBIDORES SGLT2 (iSGLT2)es_ES
dc.subjectDIABETES MELLITUSes_ES
dc.titleCriterios de uso de inhibidores de SGLT2es_ES
dc.title.alternativeGM-CCF-1454-2024es_ES
dc.typeWorking Paperes_ES


Files in this item

Thumbnail
Name:
GM-CCF-1454-2024. Criterios de ...
Size:
269.0Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record